SCHEMBL2820912

SCHEMBL2820912

O=CN(C=O)CC(=O)c1ccc(Cl)s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GSK3B P49841 1/20 0.58
F2 P00734 1/20 0.48
DAO P14920 1/20 0.48
ALDH1A1 P00352 10/20 0.45
KDM4E B2RXH2 2/20 0.45
GAA P10253 2/20 0.45
HPGD P15428 5/20 0.43
POLB P06746 3/20 0.43
CASP3 P42574 1/20 0.43
SENP8 Q96LD8 1/20 0.43
SENP7 Q9BQF6 1/20 0.43
SENP6 Q9GZR1 1/20 0.43
KMT2A Q03164 6/20 0.43
MAPT P10636 5/20 0.43
MEN1 O00255 5/20 0.43
MAPK1 P28482 2/20 0.42
MAOA P21397 2/20 0.41
MAOB P27338 2/20 0.41
BCHE P06276 1/20 0.41
NPC1 O15118 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27754293 1.00 GSK3B (0.58) GSK3BF2DAOALDH1A1KDM4E
SCHEMBL2560759 0.77 GSK3B (0.63) GSK3BF2DAOALDH1A1KDM4E
SCHEMBL15988636 0.75 GSK3B (0.73) GSK3BF2DAOALDH1A1KDM4E
SCHEMBL27783588 0.74 GSK3B (0.59) GSK3BF2DAOALDH1A1KDM4E
SCHEMBL1985851 0.74 GSK3B (0.70) GSK3BF2DAOALDH1A1KDM4E
SCHEMBL3999321 0.74 GSK3B (1.00) GSK3BF2DAOALDH1A1KDM4E
SCHEMBL2820919 0.72 GSK3B (0.58) GSK3BF2DAOALDH1A1KDM4E
SCHEMBL17459466 0.72 GSK3B (0.68) GSK3BF2DAOALDH1A1KDM4E
SCHEMBL230769 0.72 GSK3B (0.68) GSK3BF2DAOALDH1A1KDM4E
SCHEMBL23470265 0.71 GSK3B (0.40) GSK3BF2DAOALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100256165-A1 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER HONGU MITSUYA 2010-10-07 US disclosed
US-7759373-B2 Large conductance calcium-activated K channel opener MITSUBISHI TANABE PHARMA CORPORATION (JP) 2010-07-20 US disclosed
CN-100540538-C High Conductivity Calcium-Activated K Channel Opener TANABE SEIYAKU CO (JP) 2009-09-16 CN disclosed
CN-101519386-A High Conductivity Calcium-Activated K Channel Opener TANABE SEIYAKU CO (JP) 2009-09-02 CN disclosed
US-20040127527-A1 Large conductance calcium-activated k channel opener MITSUBISHI TANABE PHARMA CORPORATION (JP) 2004-07-01 US disclosed
EP-1432690-A2 IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE Tanabe Seiyaku Co., Ltd. (JP) 2004-06-30 EP disclosed
CN-1503786-A High Conductivity Calcium-Activated K Channel Opener ������ҩ��ʽ���� 2004-06-09 CN disclosed
WO-2002083111-A2 IMIDAZOLE, THIAZOLE AND OXAZOLE DERIVATIVES AND THEIR USE FOR THE MANUFACTURE OF A MEDICAMENT FOR THE TREATMENT AND/OR PREVENTION OF POLLAKIURIA OR URINARY INCONTINENCE TANABE SEIYAKU CO., LTD. (JP) 2002-10-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100256165-A1 LARGE CONDUCTANCE CALCIUM-ACTIVATED K CHANNEL OPENER KCNN3, KCNN2, KCNN1 GSK3B 4364/4885F2 2242/4885DAO 1911/4885
US-20040127527-A1 Large conductance calcium-activated k channel opener KCNN1, KCNN4, KCNN3 GSK3B 4173/4885F2 3780/4885DAO 1959/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.